Treffer: Machine Learning-Based Identification of Novel Exosome-Derived Metabolic Biomarkers for the Diagnosis of Systemic Lupus Erythematosus and Differentiation of Renal Involvement.
Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020;172(11):ITC81–96.
Robinson J. The patient's journey: systemic lupus erythematosus. BMJ. 2006;332(7554):1374–1376. (PMID: 10.1136/bmj.332.7554.1374167632501476729)
Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825–835. (PMID: 10.2215/CJN.0578061627821390)
Yu C, Li P, Dang X, et al. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022;132:102871. (PMID: 10.1016/j.jaut.2022.10287135999111)
Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24(9):1357–1366. (PMID: 10.1681/ASN.2013010026239297713752952)
Mejia-Vilet JM, Malvar A, Arazi A, et al. The lupus nephritis management renaissance. Kidney Int. 2022;101(2):242–255. (PMID: 10.1016/j.kint.2021.09.01234619230)
Gasparotto M, Gatto M, Binda V, et al. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford). 2020;59(Suppl5):v39–v51. (PMID: 10.1093/rheumatology/keaa381332800157751166)
Zhao M, Zhou Y, Zhu B, et al. IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus. Ann Rheum Dis. 2016;75(11):1998–2006. (PMID: 10.1136/annrheumdis-2015-20841026787370)
Yang P, Zhang X, Chen S, et al. A Novel Serum tsRNA for Diagnosis and Prediction of Nephritis in SLE. Front Immunol. 2021;12:735105. (PMID: 10.3389/fimmu.2021.735105348679558632637)
Kidney Disease: Improving Global Outcomes Lupus Nephritis Work G. KDIGO 2024 Clinical Practice Guideline for the management of Lupus Nephritis. Kidney Int. 2024;105(1S):S1–S69.
Yang P, Sun Y, Wang C, et al. Serum exosomal tsRNA biomarkers: A novel strategy for identifying lupus nephritis. Clin Transl Med. 2024;14(5):e1677. (PMID: 10.1002/ctm2.16773876089211101668)
Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
Yu W, Hurley J, Roberts D, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32(4):466–477. (PMID: 10.1016/j.annonc.2021.01.07433548389)
Yu D, Li Y, Wang M, et al. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer. 2022;21(1):56. (PMID: 10.1186/s12943-022-01509-9351808688855550)
Chen S, Zhang X, Meng K, et al. Urinary exosome tsRNAs as novel markers for diagnosis and prediction of lupus nephritis. Front Immunol. 2023;14:1077645. (PMID: 10.3389/fimmu.2023.1077645368451419946979)
Chen F, Shi B, Liu W, et al. Circulating exosomal microRNAs as biomarkers of lupus nephritis. Front Immunol. 2023;14:1326836. (PMID: 10.3389/fimmu.2023.13268363822350610785001)
Chen YM, Tang KT, Liu HJ, et al. tRF-His-GTG-1 enhances NETs formation and interferon-alpha production in lupus by extracellular vesicle. Cell Commun Signal. 2024;22(1):354. (PMID: 10.1186/s12964-024-01730-73897297511229248)
Dou R, Zhang X, Xu X, et al. Mesenchymal stem cell exosomal tsRNA-21109 alleviate systemic lupus erythematosus by inhibiting macrophage M1 polarization. Mol Immunol. 2021;139:106–114. (PMID: 10.1016/j.molimm.2021.08.01534464838)
Chuang HC, Chen MH, Chen YM, et al. BPI overexpression suppresses Treg differentiation and induces exosome-mediated inflammation in systemic lupus erythematosus. Theranostics. 2021;11(20):9953–9966. (PMID: 10.7150/thno.63743348157978581436)
Chuang HC, Chen MH, Chen YM, et al. Induction of Interferon-gamma and Tissue Inflammation by Overexpression of Eosinophil Cationic Protein in T Cells and Exosomes. Arthritis Rheumatol. 2022;74(1):92–104. (PMID: 10.1002/art.4192034224653)
Luo X, An M, Cuneo KC, et al. High-Performance Chemical Isotope Labeling Liquid Chromatography Mass Spectrometry for Exosome Metabolomics. Anal Chem. 2018;90(14):8314–8319. (PMID: 10.1021/acs.analchem.8b01726299200666058730)
Zhu Q, Huang L, Yang Q, et al. Metabolomic analysis of exosomal-markers in esophageal squamous cell carcinoma. Nanoscale. 2021;13(39):16457–16464. (PMID: 10.1039/D1NR04015D34648610)
Lou D, Shi K, Li HP, et al. Quantitative metabolic analysis of plasma extracellular vesicles for the diagnosis of severe acute pancreatitis. J Nanobiotechnology. 2022;20(1):52. (PMID: 10.1186/s12951-022-01239-6350904808796348)
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. (PMID: 10.1002/art.17804009289324032)
Wu LH, Yu F, Tan Y, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013;83(4):715–723. (PMID: 10.1038/ki.2012.40923302713)
Yu F, Haas M, Glassock R, et al. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483–495. (PMID: 10.1038/nrneph.2017.8528669995)
Yap DYH, Chan TM. B cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments. Int J Mol Sci. 2019;20(24):6231.
Roveta A, Parodi EL, Brezzi B, et al. Lupus Nephritis from Pathogenesis to New Therapies: An Update. Int J Mol Sci. 2024;25(16):8981.
Kronbichler A, Brezina B, Gauckler P, et al. Refractory lupus nephritis: When, why and how to treat. Autoimmun Rev. 2019;18(5):510–518. (PMID: 10.1016/j.autrev.2019.03.00430844548)
Fang Y, Ni J, Wang YS, et al. Exosomes as biomarkers and therapeutic delivery for autoimmune diseases: Opportunities and challenges. Autoimmun Rev. 2023;22(3):103260. (PMID: 10.1016/j.autrev.2022.10326036565798)
Fei Y, Liu Q, Peng N, et al. Exosomes as Crucial Players in Pathogenesis of Systemic Lupus Erythematosus. J Immunol Res. 2022;2022:8286498. (PMID: 10.1155/2022/8286498359108539328965)
Zhang L, Qing P, Yang H, et al. Gut Microbiome and Metabolites in Systemic Lupus Erythematosus: Link, Mechanisms and Intervention. Front Immunol. 2021;12:686501. (PMID: 10.3389/fimmu.2021.68650134335588)
He J, Tang D, Liu D, et al. Serum proteome and metabolome uncover novel biomarkers for the assessment of disease activity and diagnosing of systemic lupus erythematosus. Clin Immunol. 2023;251:109330. (PMID: 10.1016/j.clim.2023.10933037075949)
Sehrawat TS, Arab JP, Liu M, et al. Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. Hepatology. 2021;73(2):571–585. (PMID: 10.1002/hep.3125632246544)
Zhang Q, Li X, Yin X, et al. Metabolomic profiling reveals serum L-pyroglutamic acid as a potential diagnostic biomarker for systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(2):598–606. (PMID: 10.1093/rheumatology/keaa12632259244)
Wu CC, Huang YS, Chen JS, et al. Resveratrol ameliorates renal damage, increases expression of heme oxygenase-1, and has anti-complement, anti-oxidative, and anti-apoptotic effects in a murine model of membranous nephropathy. PLoS One. 2015;10(5):e0125726. (PMID: 10.1371/journal.pone.0125726259549694425525)
Weitere Informationen
Objective: This study aims to investigate the exosome-derived metabolomics profiles in systemic lupus erythematosus (SLE), identify differential metabolites, and analyze their potential as diagnostic markers for SLE and lupus nephritis (LN).
Methods: Totally, 91 participants were enrolled between February 2023 and January 2024 including 58 SLE patients [30 with nonrenal-SLE and 28 with Lupus nephritis (LN)] and 33 healthy controls (HC). Ultracentrifugation was used to isolate serum exosomes, which were analyzed for their metabolic profiles using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Endogenous metabolites were identified via public metabolite databases. Random Forest, Lasso regression and Support Vector Machine Recursive Feature Elimination (SVM-RFE) algorithms were employed to screen key metabolites, and a prediction model was constructed for SLE diagnosis and LN discrimination. ROC curves were constructed to determine the potential of these differential exosome-derived metabolites for the diagnosis of SLE. Furthermore, Spearman's correlation was employed to evaluate the potential links between exosome-derived metabolites and the clinical parameters which reflect disease progression.
Results: A total of 586 endogenous serum exosome-derived metabolites showed differential expression, with 225 exosome-derived metabolites significantly upregulated, 88 downregulated and 273 exhibiting no notable changes in the HC and SLE groups. Machine learning algorithms revealed three differential metabolites: Pro-Asn-Gln-Met-Ser, C24:1 sphingolipid, and protoporphyrin IX, which exhibited AUC values of 0.998, 0.992 and 0.969 respectively, for distinguishing between the SLE and HC groups, with a combined AUC of 1.0. In distinguishing between the LN and SLE groups, the AUC values for these metabolites were 0.920, 0.893 and 0.865, respectively, with a combined AUC of 0.931, demonstrating excellent diagnostic performance. Spearman correlation analysis revealed that Pro-Asn-Gln-Met-Ser and protoporphyrin IX were positively correlated with the SLE Disease Activity Index (SLEDAI) scores, urinary protein/creatinine ratio (ACR) and urinary protein levels, while C24:1 sphingolipid exhibited a negative correlation.
Conclusions: This study provides the first comprehensive characterization of the exosome-derived metabolites in SLE and established a promising prediction model for SLE and LN discrimination. The correlation between exosome-derived metabolites and key clinical parameters strongly indicated their potential role in SLE pathological progression.
(© 2025. The Author(s), under exclusive licence to Huazhong University of Science and Technology.)
Declarations. Conflict of interest: The authors have no conflict of interest.